Clinical Trial Update: A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nivolumab plus chemotherapy or nivolumab plus ipilimumab versus chemotherapy in EGFR-mutant NSCLC after failure of 1L/2L EGFR TKIs; stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Nivolumab + Chemotherapy
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)
• nivolumab/ipilimumab

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Small-Cell Lung Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2023-02-06